Nutrition and somatomedin XXII: Molecular regulation of insulin-like growth factor-I during fasting and refeeding in rats

1991 ◽  
Vol 6 (1) ◽  
pp. 33-43 ◽  
Author(s):  
S. Goldstein ◽  
J. B. Harp ◽  
L. S. Phillips

ABSTRACT The liver is thought to be the locus of nutritional/hormonal regulation of circulating insulin-like growth factor-I (IGF-I). To probe the basis of nutritional regulation, we examined changes in serum IGF-I, hepatic content of extractable IGF-I immunoreactivity (a high Mr putative precursor) and hepatic IGF-I mRNA during fasting and refeeding in rats. Preliminary studies revealed that the hepatic level of IGF-I mRNA was consistently reduced only after food was withheld for 3 days, so the effects of refeeding were subsequently examined in such animals. After 3 days of fasting, animals lost 30% of their initial weight; weight regain was apparent within 3 h of refeeding ad libitum and, after 48 h, weight was comparable to initial fed levels. Fasting reduced levels of serum and extractable hepatic IGF-I to 19 and 26% of control (fed) values respectively (both P<0·005 vs control). There was no change in levels of serum IGF-I over the first 3 h of refeeding, but IGF-I rose above fasted levels at both 9 and 48 h (both P<0·005). Extractable hepatic IGF-I rose more slowly and was still below fasted levels after 9 h of refeeding, and modestly, but not significantly, greater than fasted levels after 48 h. The ratio of serum to hepatic IGF-I was decreased compared with control after 3 days of fasting, but increased after 3 and 9 h of refeeding (P<0·02 at 9 h). Northern blot analysis of total hepatic RNA revealed four species of IGF-I mRNA 0·8–1·1, 2·0, 4·0 and 7·5 kb in size. Each mRNA species fell to 15–28% of control levels after 3 days of fasting (all P<0·001). There was a prompt increase in each transcript after 3 h of refeeding, and all values were significantly (P<0·05) greater than fasted levels at 9 h but, at 48 h, most species were still below control levels. Levels of mRNA for the cytoskeletal proteins β-actin and cyclophilin also fell with fasting, but were restored more rapidly than IGF-I mRNA, to or above control levels after 3 h of refeeding. The observation that IGF-I expression was decreased at 3 h when β-actin and cyclophilin were normalized suggests specificity of regulation. Despite the temporal incongruity between IGF-I mRNA and serum and hepatic IGF-I, there were highly significant correlations (all P<0·002) between each pair of parameters. Since refeeding of fasted animals led to a rise in IGF-I mRNA which preceded rises in serum and hepatic IGF-I, our findings are consistent with the hypothesis that nutritional regulation of circulating IGF-I involves modulation at the level of hepatic IGF-I mRNA. The changes in the ratio of hepatic to serum IGF-I during fasting and refeeding indicate that there may also be regulation at the level of hepatic release.

1987 ◽  
Vol 115 (1) ◽  
pp. 135-139 ◽  
Author(s):  
G. Norstedt ◽  
C. Möller

ABSTRACT Primary liver cells from adult rats were used to study the hormonal regulation of mRNA coding for insulin-like growth factor I (IGF-I). IGF-I mRNA could be detected at a low concentration in liver cells prepared from hypophysectomized rats and cultivated for 3 days. When these cells were exposed to GH on the second day, a dose-dependent increase in IGF-I mRNA was observed. The continuous presence of serum was not a prerequisite for this response, since GH also induced IGF-I mRNA in a defined hormone-supplemented medium. It is concluded that GH can induce IGF-I mRNA in the liver by a direct mechanism. J. Endocr. (1987) 115, 135–139


2013 ◽  
Vol 125 (6) ◽  
pp. 265-280 ◽  
Author(s):  
Callum Livingstone

IGF-I (insulin-like growth factor-I) is a peptide hormone, produced predominantly by the liver in response to pituitary GH (growth hormone), which is involved in a wide variety of physiological processes. It acts in an endocrine, paracrine and autocrine manner to promote growth. The production of IGF-I signals the availability of nutrients needed for its anabolic actions. Recently, there has been growing interest in its role in health and disease. IGF-I has long been known to be regulated by nutrition and dysregulated in states of under- and over-nutrition, its serum concentrations falling in malnutrition and responding promptly to refeeding. This has led to interest in its utility as a nutritional biomarker. A considerable evidence base supports utility for measurement of IGF-I in nutritional contexts. Its concentration may be valuable in providing information on nutritional status, prognosis and in monitoring nutritional support. However, it is insufficiently specific for use as a screening test for under nutrition as its serum concentration is influenced by many factors other than nutritional status, notably the APR (acute-phase response) and endocrine conditions. Concentrations should be interpreted along with clinical findings and the results of other investigations such as CRP (C-reactive protein). More recently, there has been interest in free IGF-I which holds promise as a nutritional marker. The present review covers nutritional regulation of IGF-I and its dysregulation in disease, then goes on to review recent studies supporting its utility as a nutritional marker in clinical contexts. Although not currently recommended by clinical guidelines, it is likely that, in time, measurement of IGF-I will become a routine part of nutritional assessment in a number of these contexts.


Sign in / Sign up

Export Citation Format

Share Document